<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Methocarbamol: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Methocarbamol: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Methocarbamol: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9628" href="/d/html/9628.html" rel="external">see "Methocarbamol: Drug information"</a> and <a class="drug drug_patient" data-topicid="10854" href="/d/html/10854.html" rel="external">see "Methocarbamol: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F194398"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Robaxin [DSC];</li>
<li>Robaxin-750 [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867508"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Robaximol [DSC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1060295"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Skeletal Muscle Relaxant, Nonparalytic</span></li></ul></div>
<div class="block dop drugH1Div" id="F194416"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f39989a2-6f20-4128-bfd3-a7eb8e650e81">Muscle spasm</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Muscle spasm: </b>Adolescents ≥16 years: Oral: 1,500 mg 4 times daily for 2 to 3 days; maximum daily dose: 8 g/<b>day</b> (reserved for severe conditions); then decrease dose to 4,000 to 4,500 mg/day in 3 to 6 divided doses (ie, 1,000 mg 4 times daily or 750 mg every 4 hours or 1,500 mg 3 times daily).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b560ac83-06b3-4994-895f-215c974f7544">Postoperative pain, adjunct</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Postoperative pain, adjunct:</b> Very limited data available. <b>Note:</b> Use described in patients following minimally invasive repair of pectus excavatum and spinal fusion surgery as part of a multimodal postoperative pain protocol (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36281540','lexi-content-ref-12874691','lexi-content-ref-32766507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36281540','lexi-content-ref-12874691','lexi-content-ref-32766507'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥4 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Postoperative day (POD) 0:</p>
<p style="text-indent:-2em;margin-left:8em;">IV: 10 mg/kg/dose every 6 to 8 hours for 48 to 72 hours. Maximum adult daily dose: 3,000 mg/<b>day</b> for no more than 3 consecutive days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36281540','lexi-content-ref-12874691','lexi-content-ref-32766507','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36281540','lexi-content-ref-12874691','lexi-content-ref-32766507','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">POD 2 or 3:</p>
<p style="text-indent:-2em;margin-left:8em;">Oral: 10 mg/kg/dose every 6 to 8 hours. Maximum adult daily dose: 4,000 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36281540','lexi-content-ref-12874691','lexi-content-ref-32766507','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36281540','lexi-content-ref-12874691','lexi-content-ref-32766507','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="52f26aeb-8096-4aee-987a-92382ab5d9d0">Tetanus</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tetanus: Note:</b> Use has generally been replaced by other agents (eg, benzodiazepines) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11348815']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11348815'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV: 15 mg/kg/dose or 500 mg/<b>m<sup>2</sup></b>/dose; may repeat every 6 hours as needed; usual adult dose: 1,000 to 2,000 mg/dose; maximum total dose: 1.8 g/<b>m<sup>2</sup></b> for 3 days; in adults, injection is not recommended for use longer than 3 days.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51129915"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling; however, administration of the parenteral formulation is contraindicated in patients with renal dysfunction due to the presence of polyethylene glycol.</p></div>
<div class="block dohp drugH1Div" id="F51129916"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, elimination may be reduced in patients with cirrhosis.</p></div>
<div class="block doa drugH1Div" id="F194401"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9628" href="/d/html/9628.html" rel="external">see "Methocarbamol: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f39989a2-6f20-4128-bfd3-a7eb8e650e81">Muscle spasm</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Muscle spasm:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For skeletal muscle spasm and/or pain (eg, low back pain, neck pain) with muscle spasm, usually in combination with a nonsteroidal anti-inflammatory drug and/or acetaminophen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28192790','lexi-content-ref-12973146']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28192790','lexi-content-ref-12973146'])">Ref</a></span>). In general, muscle relaxants should be used temporarily (eg, for a few days or intermittently for a few days when needed) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 1.5 g 3 to 4 times daily for 2 to 3 days (up to 8 g/day may be given in severe conditions), then decrease dose to ≤4.5 g/day in 3 to 4 divided doses (eg, 1.5 g 3 times daily or 750 mg 4 times daily) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26168743','lexi-content-ref-29089169','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26168743','lexi-content-ref-29089169','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM, IV:</b> Initial: 1 g; may repeat every 8 hours; maximum dose: 3 g/day for no more than 3 consecutive days. If condition persists, may repeat course of therapy after a drug-free interval of 48 hours.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991144"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Use contraindicated in patients with kidney impairment due to the presence of polyethylene glycol (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Altered kidney function:</b> Mild to severe impairment: Limited data suggest no dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2253675','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2253675','lexi-content-ref-Expert.DOR'])">Ref</a></span>); use with caution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unknown dialyzability: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2253675']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2253675'])">Ref</a></span>); drowsiness has been described in patients with end-stage kidney disease (ESKD) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2253675']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2253675'])">Ref</a></span>); use with caution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis:</b> Unknown dialyzability: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>); drowsiness has been described in patients with ESKD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2253675']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2253675'])">Ref</a></span>); use with caution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988480"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment provided in manufacturer’s labeling. However, elimination may be reduced in patients with cirrhosis.</p></div>
<div class="block arsc drugH1Div" id="F56344087"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">CNS effects and fall/injury risk</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Methocarbamol may cause CNS effects, including (but not limited to) <b>dizziness</b> and <b>drowsiness</b>, which may impair physical or mental abilities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30444744','lexi-content-ref-29089169','lexi-content-ref-1501118']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30444744','lexi-content-ref-29089169','lexi-content-ref-1501118'])">Ref</a></span>). <b>Confusion </b>and <b>sedated state</b> may also occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1501118']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1501118'])">Ref</a></span>). Methocarbamol has been associated with an increased risk of <b>accidental injury</b> (including <b>falling </b>and <b>bone fracture</b>) in older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23821610']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23821610'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Related to the pharmacologic action (ie, global CNS depression) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30444744']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30444744'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Continuous use within the prior 60 days (increased risk of injuries in older adults) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23821610']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23821610'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of alcohol or other CNS depressants</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (&gt;65 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20606016']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20606016'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F194367"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia, flushing, hypotension, syncope, thrombophlebitis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus, skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dyspepsia, nausea, vomiting</p>
<p style="text-indent:0em;margin-left:2em;">Hematologic &amp; oncologic: Leukopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Cholestatic jaundice, jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Local skin exfoliation (injection), pain at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Amnesia, ataxia, confusion, headache, insomnia, metallic taste, sedated state, seizure, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, conjunctivitis, diplopia, nystagmus disorder</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasal congestion</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (Friedman 2018), drowsiness (Friedman 2018), falling (Spence 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Bone fracture (Spence 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Accidental injury (Spence 2013)</p></div>
<div class="block coi drugH1Div" id="F194381"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to methocarbamol or any component of the formulation; renal impairment (injection formulation)</p></div>
<div class="block war drugH1Div" id="F194364"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Plasma protein binding and clearance are decreased and the half-life is increased in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use of IV formulation is contraindicated.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorder: Use the oral formulation with caution in patients with a history of seizure disorder. Intravenous administration to patients with a seizure disorder is not recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: IV formulation: Recommended only for the treatment of tetanus in pediatric patients.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Injection: Contraindicated in renal impairment. Contains polyethylene glycol. Rate of injection should not exceed 3 mL/minute; solution is hypertonic; avoid extravasation.</p></div>
<div class="block foc drugH1Div" id="F194375"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Robaxin: 1000 mg/10 mL (10 mL [DSC]) [pyrogen free; contains polyethylene glycol 300 (peg-6)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1000 mg/10 mL (10 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Robaxin: 1000 mg/10 mL (10 mL [DSC]) [contains polyethylene glycol 300 (peg-6)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1000 mg/10 mL (10 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Robaxin-750: 750 mg [DSC] [contains fd&amp;c yellow #6 (sunset yellow), quinoline yellow (d&amp;c yellow #10), saccharin sodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg, 750 mg, 1000 mg [DSC]</p></div>
<div class="block geq drugH1Div" id="F194360"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F194383"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Methocarbamol Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 mg/10 mL (per mL): $0.75 - $2.06</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Methocarbamol Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $0.13 - $15.73</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">750 mg (per each): $0.17 - $0.73</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867509"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Robaximol: 100 mg/mL ([DSC])</p></div>
<div class="block admp drugH1Div" id="F52613281"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Tablet: May be crushed and mixed with food or liquid if needed.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: IV: May be directly injected undiluted at a maximum rate of 3 mL/minute; may also be further diluted and infused more slowly; patient should be in the recumbent position during and for 10 to 15 minutes after IV administration. Monitor closely for extravasation.</p></div>
<div class="block adm drugH1Div" id="F194378"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution for injection:</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">IM: A maximum of 5 mL can be administered into each gluteal region.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">IV: Maximum rate: 3 mL/minute; may be administered undiluted or diluted. Monitor closely for extravasation. Administer IV while in recumbent position. Maintain position for at least 10-15 minutes following infusion. </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet: May be crushed and mixed with food or liquid if needed.</p></div>
<div class="block sts drugH1Div" id="F194392"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution for injection: Prior to dilution, store at controlled room temperature of 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet: Store at controlled room temperature of 20°C to 25°C (68°F to 77°F).</p></div>
<div class="block usep drugH1Div" id="F53567779"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Adjunctive treatment of muscle spasm associated with acute painful musculoskeletal conditions (Oral: FDA approved in ages ≥16 years and adults; injection: FDA approved in adults); adjunctive treatment of muscle spasm associated with tetanus (Injection: FDA approved in pediatric patients [age not specified] and adults); has also been used as adjunct treatment of postoperative pain.</p></div>
<div class="block mst drugH1Div" id="F194436"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Methocarbamol may be confused with mephobarbital</p>
<p style="text-indent:-2em;margin-left:4em;">Robaxin may be confused with ribavirin, Skelaxin</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Methocarbamol is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) because most muscle relaxants are poorly tolerated in older adults due to anticholinergic effects caused by some muscle relaxants, risk of sedation, and an increased risk of fracture. In addition, efficacy is questionable at doses tolerated by geriatric patients (Beers Criteria [AGS 2023]).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Robaxin [US, Canada, Great Britain, Greece, Spain] may be confused with Rubex brand name for ascorbic acid [Ireland]; doxorubicin [Brazil]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299688"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F194369"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Botulinum Toxin-Containing Products: Muscle Relaxants (Centrally Acting) may enhance the adverse/toxic effect of Botulinum Toxin-Containing Products. Specifically, the risk for increased muscle weakness may be enhanced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eperisone: May enhance the adverse/toxic effect of Methocarbamol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolperisone: May enhance the adverse/toxic effect of Muscle Relaxants (Centrally Acting). Management: Monitor for increased sedation or CNS effects if tolperisone is combined with other centrally acting muscle relaxants. Consider decreasing the tolperisone dose if these agents are combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F194384"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal reproduction studies have not been conducted. The manufacturer notes that fetal and congenital abnormalities have been reported following in utero exposure (Hall 1982).</p></div>
<div class="block mopp drugH1Div" id="F53567778"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CNS status; IV site; heart rate and blood pressure with IV administration.</p></div>
<div class="block pha drugH1Div" id="F194363"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Causes skeletal muscle relaxation by general CNS depression</p></div>
<div class="block phk drugH1Div" id="F194380"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: Muscle relaxation: Oral: ~30 minutes </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: 46% to 50% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic via dealkylation and hydroxylation </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: 1 to 2 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: Oral: 1 to 2 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (primarily as metabolites)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Clearance: Adults: 0.2 to 0.8 L/hour/kg </p></div>
<div class="block phksp drugH1Div" id="F51159477"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Clearance is decreased ~40% in patients with severe renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Clearance is decreased ~70%; t<sub>
<sup>1</sup>/<sub>2</sub></sub> is prolonged ~3-fold in cirrhosis patients.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F194385"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Robaxin</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Metoflex</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Lumirelax</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Carbarel | Luxafar | Luxakres | Metocarbamol | Mioflex | Plewin | Reflexal | Relansol | Robaxin | Sinaxar</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Dolovisano Methocarbamol | Methocarbamol al | Methocarbamol neuraxpharm | Methocarbamol stada | Ortoton | Ortoton forte</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Metocarbamol</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Metocarbamol</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Robaxin</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Lumirelax</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Methocarbamol aristo | Methocarbamol neuraxpharm | Robaxin</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Robaxin</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Robinax</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Carbametin | Methocabal | Methocarbamol mita | Ohlaxin | Robaxin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Bc methocarbamol | C tri Methocarbamol | Caramol | Carba | Carbamol | Carmol | Carsin | Catar | Catareo | Cmg methocarbamol | Dibefanil | Hanall methocarbamol | Jr methocarbamol | Mebaron | Meca | Mecaba | Medamol | Medoran | Merbamol | Merkan | Meroca | Methoca | Methocaba | Methona | Methosi | Meto | Metocamol | Mimotyl | New-rexan | Quicksmol | Tobaxin</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Robaxin</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Lumirelax</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Ortoton</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Remisol plus | Rexivin</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Dorbaxin | Kinthomol | Robaxol</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Ortoton | Robaxin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Robaxin | Robomol</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Metoflex</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Robaxin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Fob Carbamol | Laxan | Manic | Mebamol | Metcamol | Methamol | Musxan | Myocin | Myomethol</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Ortoton</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Miyokalm</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Bolaxin | Fubaxin | Rebamol | Robaxin | Taspan</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Metocarbamol</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Mibelaxol | Oritamol</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Robaxin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methocarbamol-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30444744">
<a name="30444744"></a>Abd-Elsalam S, Arafa M, Elkadeem M, et al. Randomized-controlled trial of methocarbamol as a novel treatment for muscle cramps in cirrhotic patients. <i>Eur J Gastroenterol Hepatol</i>. 2019;31(4):499-502. doi:10.1097/MEG.0000000000001310<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methocarbamol-pediatric-drug-information/abstract-text/30444744/pubmed" id="30444744" target="_blank">30444744</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-APS.1">
<a name="APS.1"></a>American Pain Society. <i>Principles of Analgesic Use.</i> 7th ed. Chicago, IL: American Pain Society; 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36281540">
<a name="36281540"></a>Boisvert-Plante V, Poulin-Harnois C, Ingelmo P, Einhorn LM. What we know and what we don't know about the perioperative use of methadone in children and adolescents. <i>Paediatr Anaesth</i>. 2023;33(3):185-192. doi:10.1111/pan.14584<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methocarbamol-pediatric-drug-information/abstract-text/36281540/pubmed" id="36281540" target="_blank">36281540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28192790">
<a name="28192790"></a>Chou R, Deyo R, Friedly J, et al. Systemic pharmacologic therapies for low back pain: a systematic review for an American College of Physicians clinical practice guideline. <i>Ann Intern Med.</i> 2017;166(7):480-492. doi: 10.7326/M16-2458.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methocarbamol-pediatric-drug-information/abstract-text/28192790/pubmed" id="28192790" target="_blank">28192790</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26168743">
<a name="26168743"></a>Emrich OM, Milachowski KA, Strohmeier M. Methocarbamol in acute low back pain. A randomized double-blind controlled study [published correction appears in <i>MMW Fortschr Med</i>. 2019;161(suppl 6):2]. <i>MMW Fortschr Med.</i> 2015;157(suppl 5):9-16. doi: 10.1007/s15006-015-3307-x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methocarbamol-pediatric-drug-information/abstract-text/26168743/pubmed" id="26168743" target="_blank">26168743</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29089169">
<a name="29089169"></a>Friedman BW, Cisewski D, Irizarry E, et al. A randomized, double-blind, placebo-controlled trial of naproxen with or without orphenadrine or methocarbamol for acute low back pain. <i>Ann Emerg Med.</i> 2018;71(3):348-356.e5. doi: 10.1016/j.annemergmed.2017.09.031.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methocarbamol-pediatric-drug-information/abstract-text/29089169/pubmed" id="29089169" target="_blank">29089169</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20606016">
<a name="20606016"></a>Golden AG, Ma Q, Nair V, Florez HJ, Roos BA. Risk for fractures with centrally acting muscle relaxants: an analysis of a national Medicare Advantage claims database. <i>Ann Pharmacother</i>. 2010;44(9):1369-1375. doi:10.1345/aph.1P210<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methocarbamol-pediatric-drug-information/abstract-text/20606016/pubmed" id="20606016" target="_blank">20606016</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7101197">
<a name="7101197"></a>Hall JG, Reed SD. Teratogens associated with congenital contractures in humans and in animals. <i>Teratology</i>. 1982;25(2):173-191.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methocarbamol-pediatric-drug-information/abstract-text/7101197/pubmed" id="7101197" target="_blank">7101197</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11348815">
<a name="11348815"></a>Hsu SS, Groleau G. Tetanus in the emergency department: a current review. <i>J Emerg Med</i>. 2001;20(4):357-365.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methocarbamol-pediatric-drug-information/abstract-text/11348815/pubmed" id="11348815" target="_blank">11348815</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12874691">
<a name="12874691"></a>Inge TH, Owings E, Blewett CJ, et al. Reduced hospitalization cost for patients with pectus excavatum treated using minimally invasive surgery. <i>Surg Endosc</i>. 2003;17(10):1609-1613. doi:10.1007/s00464-002-8767-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methocarbamol-pediatric-drug-information/abstract-text/12874691/pubmed" id="12874691" target="_blank">12874691</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Granulation.1">
<a name="Granulation.1"></a>Methocarbamol tablet, USP [prescribing information]. Edison, NJ: AustarPharma LLC; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Granulation.2">
<a name="Granulation.2"></a>Methocarbamol tablet, USP [prescribing information]. Fairfield, NJ: Granulation Technology, Inc; May 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NCQA.1">
<a name="NCQA.1"></a>National Committee for Quality Assurance. Healthcare Effectiveness Data and Information Set (HEDIS). Use of high-risk medications in the elderly (DAE). https://www.ncqa.org/hedis/measures/hedis-2017-national-drug-code-ndc-license/hedis-2017-final-ndc-lists. Published 2017. Accessed December 19, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-13854387">
<a name="13854387"></a>Poppen JL, Flanagan ME. Use of methocarbamol for muscle spasm after lumbar and cervical laminectomies. <i>J Am Med Assoc</i>. 1959;171:298-299. doi:10.1001/jama.1959.73010210003013a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methocarbamol-pediatric-drug-information/abstract-text/13854387/pubmed" id="13854387" target="_blank">13854387</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1501118">
<a name="1501118"></a>Preston KL, Wolf B, Guarino JJ, Griffiths RR. Subjective and behavioral effects of diphenhydramine, lorazepam and methocarbamol: evaluation of abuse liability. <i>J Pharmacol Exp Ther</i>. 1992;262(2):707-720.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methocarbamol-pediatric-drug-information/abstract-text/1501118/pubmed" id="1501118" target="_blank">1501118</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-West-Ward.1">
<a name="West-Ward.1"></a>Robaxin (methocarbamol) [prescribing information]. Eatontown, NJ: West-Ward; October 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Endo.1">
<a name="Endo.1"></a>Robaxin and Robaxin-750 (methocarbamol) [prescribing information]. Malvern, PA: Endo Pharmaceuticals Inc; January 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2253675">
<a name="2253675"></a>Sica DA, Comstock TJ, Davis J, et al. Pharmacokinetics and protein binding of methocarbamol in renal insufficiency and normals. <i>Eur J Clin Pharmacol</i>. 1990;39(2):193-194. doi:10.1007/BF00280060<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methocarbamol-pediatric-drug-information/abstract-text/2253675/pubmed" id="2253675" target="_blank">2253675</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23821610">
<a name="23821610"></a>Spence MM, Shin PJ, Lee EA, Gibbs NE. Risk of injury associated with skeletal muscle relaxant use in older adults. <i>Ann Pharmacother</i>. 2013;47(7-8):993-998.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methocarbamol-pediatric-drug-information/abstract-text/23821610/pubmed" id="23821610" target="_blank">23821610</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12973146">
<a name="12973146"></a>van Tulder MW, Touray T, Furlan AD, Solway S, Bouter LM; Cochrane Back Review Group. Muscle relaxants for nonspecific low back pain: a systematic review within the framework of the Cochrane Collaboration. <i>Spine (Phila Pa 1976).</i> 2003;28(17):1978-1992.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methocarbamol-pediatric-drug-information/abstract-text/12973146/pubmed" id="12973146" target="_blank">12973146</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32766507">
<a name="32766507"></a>Ye J, Myung K, Packiasabapathy S, et al. Methadone-based multimodal analgesia provides the best-in-class acute surgical pain control and functional outcomes with lower opioid use following major posterior fusion surgery in adolescents with idiopathic scoliosis. <i>Pediatr Qual Saf</i>. 2020;5(4):e336. doi:10.1097/pq9.0000000000000336<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methocarbamol-pediatric-drug-information/abstract-text/32766507/pubmed" id="32766507" target="_blank">32766507</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12593 Version 623.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
